On the other hand, CD133+ as well as CD133− metastatic colon cancer cells were shown to be able to form new tumors and their expression does not seem to be restricted to the stem cell compartment, which indicates that use of CD133 as a CSC marker is questionable [60,61,62]. This evidence concerns the gene PROM1 and malignant colon neoplasm.